Drawbridge Health and the Medical Research Council (MRC) Epidemiology Unit at the University of Cambridge announced the use of the OneDraw Blood Collection Device for remote blood-sample collection in a large-scale surveillance study currently being conducted to assess the prevalence of previous COVID-19 infections, according to a press release.
The study, which was launched in July 2020 and has recruited 4,000 participants, is led by Nick Wareham, Director of the MRC Epidemiology Unit and Chief Investigator of the Fenland COVID-19 Study. The primary aim of this study is to quantify the proportion of people who have been previously infected with COVID-19 in the Fenland cohort, which is broadly representative of the population of Cambridgeshire, a county in the East of England.
The OneDraw Blood Collection Device is being used in the study to obtain remote blood samples from participants for repeated COVID-19 serological testing over a nine to 12-month period. The device allows study participants to collect blood samples at home, which can then be sent to the clinical testing laboratory for analysis, without the need for face-to-face interaction with a study team member, minimizing virus exposure and potential spread.
